La rosuvastatina: aspetti farmacologici.

Translated title of the contribution: Rosuvastatin: pharmacologic features

Franco Bernini, Alberico L. Catapano

Research output: Contribution to journalArticlepeer-review


The development of more active and safe new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) will increase the armamentarium of therapeutic tools available to the physicians for antiatherosclerotic therapies. Rosuvastatin presents a promising pharmacological profile: high affinity for the enzyme, a relative high hydrophilicity, selective hepatic uptake and activity, minimal cytochrome P450-mediated metabolism. Clinically the drug displays the highest lipid-lowering efficacy in the class with a safety profile similar to the other statins. Drug interaction potential is reduced. Rosuvastatin effectively decreases triglycerides, triglyceride-rich lipoproteins, non-HDL cholesterol, and increases HDL cholesterol. All together these properties will favor the achievement of therapeutic goals in the treated patients.

Translated title of the contributionRosuvastatin: pharmacologic features
Original languageItalian
JournalItalian Heart Journal
Volume4 Suppl 7
Publication statusPublished - Dec 2003

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Rosuvastatin: pharmacologic features'. Together they form a unique fingerprint.

Cite this